DAAN Biotherapeutics, GC Cell to Advance CAR-T & CAR-NK Cell Therapies

The tumor antigen-specific antibody sequence has been licensed exclusively to GC Cell, a gene and cell Therapy Company, by DAAN Biotherapeutics, a leading novel drug development company that specializes in T-Cell receptor (TCR)-based medicines. The contract gives GC Cell the only right to use the antibody sequence of DAAN Biotherapeutics for the investigation and creation of CAR-T (chimeric antigen receptor T cell) and CAR-NK (chimeric antigen receptor natural killer cell) treatments.The antibody at the heart of the deal targets a tumor antigen that has been continuously utilized by a number of pharmaceutical companies in the development of next-generation cancer medicines. This tumor antigen is greatly over expressed in major solid tumors, such as colorectal and lung malignancies.

An initial payment, milestone payments linked to the stages of development and commercialization, and royalties based on future sales are all included in the licensing agreement. To protect intellectual technology and company plans, certain financial and contractual information is kept private. Both businesses see this partnership as a critical step in the development and of cell therapies and adapt therapy for solid tumor treatment.

The antibody provided by DAAN Biotherapeutics offers enhanced specificity compared to existing antibodies, allowing it to be positioned as a promising candidate in emerging markets for cell therapies.Byoung-Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, "We will continue to innovate our technologies to develop cancer treatments that will change the lives of patients."